<DOC>
<DOCNO>EP-0612249</DOCNO> 
<TEXT>
<INVENTION-TITLE>
METHODS OF INHIBITING RESTENOSIS.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31335	A61K31335	A61K31395	A61K31395	A61K3157	A61K3157	A61K31715	A61K31715	A61K31716	A61K31724	A61K31737	A61K31737	A61K3818	A61K3818	A61K4748	A61K4748	A61L1516	A61L1528	A61L2600	A61L2600	A61L2700	A61L2720	A61L2734	A61L2736	A61L2754	A61L3300	A61L3300	A61P4300	A61P4300	C07K14435	C07K1450	C08B3700	C08B3716	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61L	A61L	A61L	A61L	A61L	A61L	A61L	A61L	A61L	A61L	A61L	A61P	A61P	C07K	C07K	C08B	C08B	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K31	A61K38	A61K38	A61K47	A61K47	A61L15	A61L15	A61L26	A61L26	A61L27	A61L27	A61L27	A61L27	A61L27	A61L33	A61L33	A61P43	A61P43	C07K14	C07K14	C08B37	C08B37	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Polyionic derivatives of cyclodextrins and methods for preparing these derivatives are provided in which a polyionic derivative of cyclodextrin is combined with a growth factor, preferably a heparin binding growth factor. These compositions are of low solubility and are applied directly to the location of a wound. By virtue of the low solubility, the compositions remain in place at the site of application and slowly release growth factor. In an alternative embodiment, the cyclodextrin derivatives are administered in the absence of growth factor and are used to absorb growth factor present in the body at the location of the wound in order to prevent overstimulation of the wound response.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
UNIV PENNSYLVANIA
</APPLICANT-NAME>
<APPLICANT-NAME>
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BARNATHAN ELLIOT
</INVENTOR-NAME>
<INVENTOR-NAME>
HERRMANN HOWARD C
</INVENTOR-NAME>
<INVENTOR-NAME>
WEISZ PAUL B
</INVENTOR-NAME>
<INVENTOR-NAME>
BARNATHAN, ELLIOT
</INVENTOR-NAME>
<INVENTOR-NAME>
HERRMANN, HOWARD, C.
</INVENTOR-NAME>
<INVENTOR-NAME>
WEISZ, PAUL B.
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 METHODS OF INHIBITING RESTENOSISCross Reference to Related ApplicationsThis is a continuation-in-part of application Serial 5 No. 790,320, filed November 12, 1991 (pending), which is a continuation-in-part of application Serial No. 691,168, filed April 24, 1991 (pending), which is a continuation of applicati Serial No. 397,559, filed August 23, 1989 (now abandoned), whi in turn is a continuation-in-part of application Serial No.10 434,659, filed November 9, 1989 (now U.S Patent No. 5,019,582) which is a continuation of application Serial No. 295,683, fil January 10, 1989 (now abandoned) , which in turn is a continuation-in-part of application Serial No. 145,407, filed January 19, 1988 (now abandoned), all of said applications and15 said patent being hereby incorporated by reference. This is also a continuation-in-part of application Serial No. 480,407, filed February 15, 1990, which is hereby incorporated by reference.0 Field of InventionThe present invention is directed to compounds, compositions and methods for healing wounded living tissue, an particularly to saccharide-based compounds and compositions which remain localized at the site of a wound for extended 5 periods of time. 

 Background of the Invention The injury of tissue initiates a series of events tha result in tissue repair and healing of the wound. During the first several days following an injury, there is directed migration of neutrophils, acrophages and fibroblasts to the site of the wound. The macrophages and fibroblasts which migrate to the wound site are activated, thereby resulting in endogenous growth factor production, synthesis of a provisional extracellular matrix, proliferation of fibroblasts and collagen synthesis. Finally from about two weeks to one year after infliction of the wound there is remodeling of the wound with active collagen turn over and cross linking (Pierce et al., 1991, J. Cell Biochem., 45:319-326). The manner in which this repair process is regulated is mostly unknown; it is known, however, that cell proliferation, migration and protein synthesis can be stimulated by growth factors that act on cells having receptors for these growth factors.In vivo studies have shown that local application of exogenous single growth factors or a combination of growth factors can enhance the healing process following experimental wounding in animals (Antoniades et al., 1991, Proc. Natl. Acad. Sci. USA, 88:565-569). The ability of these growth factors to promote wound healing has resulted in efforts to obtain these factors
</DESCRIPTION>
<CLAIMS>
What is claimed is:
1. A composition for affecting the growth of living tissue in mammals comprising a polyanionic saccharide derivative having by a body temperature solubility of less than about 15 grams/100 ml of distilled water and a physiologically acceptable carrier for the saccharide derivative.
2. The composition of claim 1 further comprising a heparin binding growth factor.
3. The composition of claim 1 wherein said saccharide derivative has on average at least about 1.4 anionic substituents per sugar unit.
4. The composition of claim 3 wherein said saccharide derivative has on average from about 1.4 to about 4 anionic substituents per sugar unit.
5. The composition of claim 3 wherein said saccharide derivative is a compound consisting of n sugar units and R anionic substituents such that when: n = 2 to 3; average anionic R per n unit = or 
>
 3.5 n = 4 to 5; average anionic R per n unit = or 
>
 2.0 n = 
>
 6; average anionic R per n unit = or 
>
 1.4.
6. The composition of claim 1 wherein said saccharide derivative comprises polyanionic cyclodextrin derivative. 


 7. The composition of claim 6 wherein said cyclodextrin derivative comprises compounds of the formula:
wherein at least two of said R groups per monomeric unit are selected from the group consisting of sulfate, phosphate, sulfonate and nitrate, and the remainder of said R groups, when present, are nonanionic groups selected from the group consisting of H, alkyl, aryl, ester, ether, thioester, thioether and -COOH; and n is an integer from about 6 to about 12.
8. The composition of claim 6 wherein said cyclodextrin derivative is comprised of one or more cyclodextrin monomers having on average at least about 10 anionic substituents per monomer.
9. The composition of claim 8 wherein said monomer has on average from about 10 to about 24 anionic substituents per monomer. 


 10. The composition of claim 7 wherein said cyclodextrin derivative comprises cyclodextrin polymer.
11. The composition of claim 10 wherein said polymer is solid particulate dispersed or suspended in said carrier.
12. The composition of claim 6 wherein said cyclodextrin derivative comprises a salt of polyanionic alpha-, beta- or gamma-cyclodextrin.
13. The composition of Claim 12 wherein the cationic constituents of said salt are selected from the group consisting essentially of Mg, Al, Ca, La, Ce, Pb, Ba and combinations of two or more of these.
14. The composition of claim 1 wherein said derivative is substantially insoluble in water at body temperature.
15. The composition of claim 1 wherein at least a portion of said saccharide derivative is solid particulate dispersed or suspended in said carrier.
16. A method for inhibiting the pathological growth of smooth muscle cells in a tissue of a mammal comprising administering locally to said tissue a polyanionic saccharide derivative in an amount effective to inhibit said pathological growth, said derivative having a solubility at body temperature of less than about 15 grams/100 ml of water.
17. The method of claim 16 wherein said derivative is a cyclodextrin derivative. 


 18. The method of claim 17 wherein the anionic substituents of said cyclodextrin derivative are selected from the group consisting essentially of sulfate, sulfonate, phosphate, nitrate and combinations of two or more of these.
19. The method of claim 18 wherein said cyclodextrin derivative comprises a salt of said polyanionic cyclodextrin.
20. The method of claim 19 wherein said derivative is combined with a non-toxic pharmaceutically acceptable carrier of physiological salinity.
21. The method of claim 16 wherein said derivative comprises a sulfated derivative of beta-cyclodextrin polymer.
22. The method of claim 16 wherein said derivative comprises solid particulate suspended or dispersed in a physiologically acceptable carrier, said suspension or dispersion comprising about 1 to about 30% by weight of said derivative.
23. The method of claim 22 wherein said suspension or dispersion comprises about 5 to about 15% by weight of said derivative.
24. The method of claim 16 wherein said derivative is combined with growth factor.
25. The method of claim 16 wherein said local administration comprises infusing the saccharide derivative directly into the tissue. 


 26. The method of claim 16 wherein said local administration comprises infusing an aqueous suspension or dispersion of said saccharide derivative directly into the tissue using an infusion balloon catheter having a plurality of holes in the wall of the balloon portion thereof.
27. A method for promoting angiogenesis in mammals comprising administering locally to a tissue to be treated a polyanionic saccharide derivative of a cyclodextrin combined with growth factor, said derivative being characterized by a solubility at body temperature of less than about 15 grams/100 ml of distilled water.
28. The method of claim 27 wherein said derivative is a cyclodextrin derivative.
29. The method of claim 28 wherein the anionic substituents of said cyclodextrin derivative are selected from the group consisting essentially of sulfate, sulfonate, phosphate, nitrate and combinations of two or more of these.
30. The method of claim 29 wherein said cyclodextrin derivative comprises a salt of said polyanionic cyclodextrin.
31. The method of claim 30 wherein said derivative is combined with a non-toxic pharmaceutically acceptable carrier of physiological salinity.
32. The method of claim 27 wherein said derivative comprises a sulfated derivative of beta-cyclodextrin polymer. 


 33. The method of claim 27 wherein said derivative comprises solid particulate suspended or dispersed in a physiologically acceptable carrier, said suspension or dispersion comprising about 1 to about 30% by weight of said derivative.
34. The method of claim 33 wherein said suspension or dispersion comprises about 5 to about 15% by weight of said derivative.
35. The method of claim 29 wherein said local administration comprises infusing the saccharide derivative directly into the tissue.
36. The method of claim 27 wherein said local administration comprises infusing an aqueous suspension or dispersion of said saccharide derivative directly into the tissue using an infusion balloon catheter having a plurality of holes in the wall of the balloon portion thereof.
37. A method for treating transplanted tissue or organs in mammals comprising contacting the organ or tissue to be transplanted with a composition comprising polyanionic derivative of a cyclodextrin and growth factor, said composition being administered in an amount effective to promote acceptance of the transplanted material in the body, wherein said derivative has a solubility at body temperature of less than about 15 grams/100 ml of water.
38. The method of claim 37 wherein said contacting step comprises administering said derivative locally to the tissue or organ. 


 39. A method for treating damaged or transplanted bone comprising contacting bone tissue with a composition comprising a polyanionic derivative of a cyclodextrin combined with a growth factor in an amount effective to promote the healing of said damaged or transplanted bone wherein said derivative has a solubility at body temperature of less than about 15 grams/100 ml of water.
40. The method of claim 39 wherein said composition further comprises bone tissue.
41. The method of claim 40 wherein said bone tissue comprises powdered bone.
42. The method of claim 40 wherein said bone tissue comprises finely dispersed demineralized bone.
43. The method of claim 40 wherein said composition comprises a paste.
44. The method of claim 40 wherein said bone tissue comprises autogenous bone.
45. The method of claim 40 wherein said bone tissue comprises xenogenus bone. 

46. A method for preparing a compound suitable for affecting the growth of living tissue in mammals, comprising: providing cyclodextrin polymer; and reacting said cyclodextrin polymer with an anionic derivatizing agent in the presence of dimethylformamide at a temperature of from about 62 to about 72Â°C for a period of about 3 to about 4 days to provide a polyanionic derivative of said cyclodextrin polymer in which the derivative is characterized by a solubility at body temperature of less than about 15 grams/100 ml of water. 

</CLAIMS>
</TEXT>
</DOC>
